Live In Play

Live In Play®

Updated: 11-Mar-22 08:05 ET

WIRES: On The Wires

Natera (NTRA) announced a milestone with over 100 sites initiated and 1,000 patients enrolled across the U.S. in its BESPOKE CRC study, a prospective, multi-center trial to measure the clinical impact of serial testing with Signatera in resectable CRC. Since its initial launch in January 2020, interest in the outcome of this trial has grown among oncologists nationwide, with a current target to enroll over 2,000 CRC patients across different stages of disease and to follow them for up to 5 years post surgery. The primary objectives of the study are to quantify the real-world impact of Signatera testing on both adjuvant treatment decisions and clinical outcomes, compared to a historical control group. The investigators plan to conduct an interim analysis later in 2022, for presentation at a future scientific congress.
PTC Therapeutics (PTCT) announced that the company will present three posters outlining data for EMFLAZA (deflazacort) in Duchenne muscular dystrophy at the Muscular Dystrophy Association Clinical & Scientific Conference being held March 13-16 in Nashville, Tenn. and virtually. For the first time, PTC will be presenting data on the association between steroid treatment and clinical outcomes among non-ambulatory patients with DMD, expanding the body of evidence that supports the potential cumulative benefit of deflazacort versus prednisone in this patient population. These results have not been previously published and further advance the clinical understanding of steroid treatment in the continuum of DMD care.